Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.24M | -2.87M | -7.03M | -6.58M | -6.30M |
| Total Depreciation and Amortization | 116.90K | 242.40K | 370.40K | 377.80K | 394.80K |
| Total Amortization of Deferred Charges | 68.80K | 79.80K | 92.00K | 92.00K | 92.00K |
| Total Other Non-Cash Items | -7.51M | -3.76M | 5.20K | -70.80K | -139.60K |
| Change in Net Operating Assets | -1.72M | -912.20K | -103.60K | -148.00K | -191.60K |
| Cash from Operations | -7.81M | -7.22M | -6.67M | -6.33M | -6.14M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 3.51M | 1.77M | 16.20K | 16.20K | 16.20K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | -63.50K | -127.50K |
| Cash from Investing | 3.51M | 1.77M | 16.20K | -47.30K | -111.30K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -126.00K | -141.50K | -157.00K | -162.00K | -167.00K |
| Issuance of Common Stock | 965.00K | 482.50K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 555.00K | 692.00K | 829.00K | 1.99M | 3.15M |
| Cash from Financing | 1.64M | 1.18M | 726.00K | 1.97M | 3.23M |
| Foreign Exchange rate Adjustments | 8.10K | 2.50K | -3.20K | -3.80K | -4.30K |
| Miscellaneous Cash Flow Adjustments | 100.00 | 0.00 | 0.00 | 100.00 | 100.00 |
| Net Change in Cash | -2.66M | -4.27M | -5.93M | -4.41M | -3.03M |